ATE226578T1 - Benzofuranderivate als tachykininantagonisten - Google Patents
Benzofuranderivate als tachykininantagonistenInfo
- Publication number
- ATE226578T1 ATE226578T1 AT94926877T AT94926877T ATE226578T1 AT E226578 T1 ATE226578 T1 AT E226578T1 AT 94926877 T AT94926877 T AT 94926877T AT 94926877 T AT94926877 T AT 94926877T AT E226578 T1 ATE226578 T1 AT E226578T1
- Authority
- AT
- Austria
- Prior art keywords
- tachykin
- antagonists
- benzofuran derivatives
- benzofuran
- derivatives
- Prior art date
Links
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical class C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939317987A GB9317987D0 (en) | 1993-08-26 | 1993-08-26 | Chemical compounds |
| PCT/EP1994/002804 WO1995006645A1 (en) | 1993-08-26 | 1994-08-25 | Benzofuran derivatives as tachykinin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE226578T1 true ATE226578T1 (de) | 2002-11-15 |
Family
ID=10741251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94926877T ATE226578T1 (de) | 1993-08-26 | 1994-08-25 | Benzofuranderivate als tachykininantagonisten |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5935972A (de) |
| EP (1) | EP0783499B1 (de) |
| JP (1) | JP3499243B2 (de) |
| AP (1) | AP9400666A0 (de) |
| AT (1) | ATE226578T1 (de) |
| AU (1) | AU7655094A (de) |
| CO (1) | CO4230233A1 (de) |
| DE (1) | DE69431604T2 (de) |
| EC (1) | ECSP941146A (de) |
| ES (1) | ES2185665T3 (de) |
| GB (1) | GB9317987D0 (de) |
| IL (1) | IL110793A (de) |
| IS (1) | IS4201A (de) |
| PE (1) | PE14995A1 (de) |
| WO (1) | WO1995006645A1 (de) |
| ZA (1) | ZA946470B (de) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
| GB9505692D0 (en) * | 1995-03-21 | 1995-05-10 | Glaxo Group Ltd | Chemical compounds |
| GB9513121D0 (en) * | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| TW458774B (en) * | 1995-10-20 | 2001-10-11 | Pfizer | Antiemetic pharmaceutical compositions |
| GB9525296D0 (en) * | 1995-12-11 | 1996-02-07 | Merck Sharp & Dohme | Therapeutic agents |
| AU714542B2 (en) * | 1996-06-26 | 2000-01-06 | Warner-Lambert Company | Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis |
| GB9614347D0 (en) * | 1996-07-09 | 1996-09-04 | Smithkline Beecham Spa | Novel compounds |
| TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
| EP1178984B1 (de) * | 1999-05-21 | 2003-03-19 | Pfizer Products Inc. | 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate |
| WO2001025233A1 (en) * | 1999-10-07 | 2001-04-12 | Hisamitsu Pharmaceutical Co., Inc. | Piperidine derivatives |
| WO2001032625A1 (en) | 1999-11-03 | 2001-05-10 | Du Pont Pharmaceuticals Company | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| AU2001253418A1 (en) * | 2000-04-12 | 2001-10-30 | Smith Kline Beecham Corporation | Compounds and methods |
| ATE367811T1 (de) * | 2000-06-12 | 2007-08-15 | Univ Rochester | Methode zur behandlung von hitzewallungen, durch verwendung eines tachikinin-rezeptor antagonisten |
| JP5132864B2 (ja) | 2000-07-11 | 2013-01-30 | アルバニー モレキュラー リサーチ， インコーポレイテッド | ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法 |
| ATE392898T1 (de) * | 2000-10-26 | 2008-05-15 | Amgen Inc | Antiphlogistische mittel |
| AU2005274927B2 (en) | 2004-07-15 | 2011-11-03 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| US7868016B2 (en) * | 2005-07-13 | 2011-01-11 | Baxter International Inc. | Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride |
| KR101594898B1 (ko) | 2005-07-15 | 2016-02-18 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8232298B2 (en) * | 2006-03-22 | 2012-07-31 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between MDM2 and P53 |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EA016079B1 (ru) | 2007-01-10 | 2012-01-30 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа | Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp) |
| JP2010516731A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物 |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| CN102014631A (zh) | 2008-03-03 | 2011-04-13 | 泰格尔医药科技公司 | 酪氨酸激酶抑制剂 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| CN102458123A (zh) | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | 芳基、杂芳基和杂环取代的四氢异喹啉及其用途 |
| US8802696B2 (en) | 2009-05-12 | 2014-08-12 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof |
| WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
| JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | ｐ５３活性を増大する置換ピペリジン及びその使用 |
| EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
| AU2011285909B2 (en) | 2010-08-02 | 2016-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| EP2606134B1 (de) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (de) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP3766975A1 (de) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina) |
| EP2654748B1 (de) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| EP2699567A1 (de) | 2011-04-21 | 2014-02-26 | Merck Sharp & Dohme Corp. | Hemmer des insulinähnlichen wachstumsfaktor-1-rezeptors |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP3358013B1 (de) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| KR20150060724A (ko) | 2012-09-28 | 2015-06-03 | 머크 샤프 앤드 돔 코포레이션 | Erk 억제제인 신규 화합물 |
| DK2925888T3 (en) | 2012-11-28 | 2017-12-18 | Merck Sharp & Dohme | COMPOSITIONS AND METHODS OF CANCER TREATMENT |
| EP2935263B1 (de) | 2012-12-20 | 2018-12-05 | Merck Sharp & Dohme Corp. | Substituierte imidazopyridine als hdm2 inhibitoren |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (de) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| EP3833668B1 (de) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| BR112021002267A8 (pt) | 2018-08-07 | 2023-02-07 | Merck Sharp & Dohme | Inibidores de prmt5 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59186969A (ja) * | 1983-04-08 | 1984-10-23 | Yoshitomi Pharmaceut Ind Ltd | ベンゾフラン−およびベンゾピランカルボキサミド誘導体 |
| US5332817A (en) * | 1990-01-04 | 1994-07-26 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles |
| US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| US5364943A (en) * | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
| US5721255A (en) * | 1992-08-19 | 1998-02-24 | Pfizer Inc. | Substituted benzylamino nitrogen containing non-aromatic heterocycles |
| IS4208A (is) * | 1993-09-22 | 1995-03-23 | Glaxo Group Limited | 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður |
| GB9426102D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
-
1993
- 1993-08-26 GB GB939317987A patent/GB9317987D0/en active Pending
-
1994
- 1994-08-23 EC EC1994001146A patent/ECSP941146A/es unknown
- 1994-08-24 ZA ZA946470A patent/ZA946470B/xx unknown
- 1994-08-25 AP APAP/P/1994/000666A patent/AP9400666A0/en unknown
- 1994-08-25 ES ES94926877T patent/ES2185665T3/es not_active Expired - Lifetime
- 1994-08-25 WO PCT/EP1994/002804 patent/WO1995006645A1/en not_active Ceased
- 1994-08-25 AT AT94926877T patent/ATE226578T1/de not_active IP Right Cessation
- 1994-08-25 US US08/793,099 patent/US5935972A/en not_active Expired - Fee Related
- 1994-08-25 CO CO94037843A patent/CO4230233A1/es unknown
- 1994-08-25 AU AU76550/94A patent/AU7655094A/en not_active Abandoned
- 1994-08-25 JP JP50792395A patent/JP3499243B2/ja not_active Expired - Fee Related
- 1994-08-25 IS IS4201A patent/IS4201A/is unknown
- 1994-08-25 EP EP94926877A patent/EP0783499B1/de not_active Expired - Lifetime
- 1994-08-25 PE PE1994249244A patent/PE14995A1/es not_active Application Discontinuation
- 1994-08-25 DE DE69431604T patent/DE69431604T2/de not_active Expired - Fee Related
- 1994-08-26 IL IL11079394A patent/IL110793A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995006645A1 (en) | 1995-03-09 |
| JP3499243B2 (ja) | 2004-02-23 |
| DE69431604T2 (de) | 2003-06-26 |
| PE14995A1 (es) | 1995-06-04 |
| EP0783499A1 (de) | 1997-07-16 |
| DE69431604D1 (de) | 2002-11-28 |
| IL110793A0 (en) | 1994-11-11 |
| JPH10508824A (ja) | 1998-09-02 |
| GB9317987D0 (en) | 1993-10-13 |
| AP9400666A0 (en) | 1994-10-31 |
| ECSP941146A (es) | 1995-01-16 |
| ES2185665T3 (es) | 2003-05-01 |
| IS4201A (is) | 1995-03-01 |
| AU7655094A (en) | 1995-03-22 |
| EP0783499B1 (de) | 2002-10-23 |
| ZA946470B (en) | 1995-11-14 |
| IL110793A (en) | 1998-09-24 |
| CO4230233A1 (es) | 1995-10-19 |
| US5935972A (en) | 1999-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69431604D1 (de) | Benzofuranderivate als tachykininantagonisten | |
| FI960156A7 (fi) | Bentsyylioksikinuklidiinit aineet P antagonisteina | |
| DE69434601D1 (de) | Markierung als Bezugspunkt | |
| IS4208A (is) | 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður | |
| DE69232003D1 (de) | Benzanilidderivate als 5-HT1D-Antagonisten | |
| FI945690L (fi) | Substituoitu N-piperidino-3-pyratsolikarboksamidi | |
| FI943976A7 (fi) | 5-aryyli-indolijohdannaiset | |
| DE69127791D1 (de) | Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten | |
| DE69605430D1 (de) | Chinolin-2-on derivate als serotonin antagonisten | |
| FI945674A7 (fi) | Substituoidut 2beta-morfoliini-androstaanijohdannaiset | |
| DE69714265D1 (de) | Tetrahydrochinolinderivate als eaa antagonisten | |
| FI940154A7 (fi) | Substituoidut dialkyylitioeetterit | |
| FI950089A7 (fi) | Dioksosyklobuteenijohdannaiset angiotensiini-II-antagonisteina | |
| FI942444A7 (fi) | Terahydropyraanijohdannaisia | |
| FI943885L (fi) | Penaami-johdannaiset | |
| FI944044L (fi) | Fenyylialkanoliamiinijohdannaiset | |
| DE59403503D1 (de) | Substituierte 1-Aryltriazolinone | |
| FI951798L (fi) | Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina | |
| DE69735811D1 (de) | Piperazinoderivate als neurokinin-antagonisten | |
| FI954614L (fi) | Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina | |
| DE69427365D1 (de) | Neue cephalosporinderivate | |
| FI944655A7 (fi) | Uudet 2,3-dihydro-2,2,4,6,7-penta-alkyyli-5-bentsofuranolit | |
| FI943513A7 (fi) | Kolekystokiniiniantagonisteina käyttökelpoisia 3-fenyyliureidoatsepin- 2-oneja ja -bentsatsepin-2-oneja | |
| NO924745D0 (no) | Benzofuraner | |
| NO921942L (no) | Benzofuranderivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |